metaEvidence - overview


			deaths (OS)
mUC - L2 - all population metastatic/advanced UC (mUC) - 2nd Line (L2) mUC - L2 - all population
versus Standard of Care (SoC)
	atezolizumab alone vs. Standard of Care (SoC)	1	0.85 [0.73; 0.99], 1 RCT, I2=0% unassessable degree of certainty
	pembrolizumab alone vs. Standard of Care (SoC)	1	0.73 [0.59; 0.91], 1 RCT, I2=0% conclusive unassessable degree of certainty
mUC - L2 - PDL1 positive metastatic/advanced UC (mUC) - 2nd Line (L2) mUC - L2 - PDL1 positive
versus Standard of Care (SoC)
	atezolizumab alone vs. Standard of Care (SoC)	2	0.87 [0.72; 1.06], 1 RCT, I2=0% inconclusive result
	pembrolizumab alone vs. Standard of Care (SoC)	1	0.57 [0.37; 0.88], 1 RCT, I2=0% conclusive unassessable degree of certainty